No abstract

BackgroundMental health is a significant contributor to global burden of disease and the consequences of perinatal psychiatric morbidity can be substantial. We aimed to obtain global estimates of puerperal psychosis prevalence based on population-based samples and to understand how postpartum psychosis is assessed and captured among included studies.MethodsIn June 2014, we searched PubMed, CiNAHL, EMBASE, PsycINFO, Sociological Collections, and Global Index Medicus for publications since the year 1990. Criteria for inclusion in the systematic review were: use of primary data relevant to pre-defined mental health conditions, specified dates of data collection, limited to data from 1990 onwards, sample size >200 and a clear description of methodology. Data were extracted from published peer reviewed articles.ResultsThe search yielded 24,273 publications, of which six studies met the criteria. Five studies reported incidence of puerperal psychosis (ranging from 0.89 to 2.6 in 1000 women) and one reported prevalence of psychosis (5 in 1000). Due to the heterogeneity of methodologies used across studies in definitions and assessments used to identify cases, data was not pooled to calculate a global estimate of risk.ConclusionsThis review confirms the relatively low rate of puerperal psychosis; yet given the potential for serious consequences, this morbidity is significant from a global public health perspective. Further attention to consistent detection of puerperal psychosis can help provide appropriate treatment to prevent harmful consequences for both mother and baby.Electronic supplementary materialThe online version of this article (doi:10.1186/s12888-017-1427-7) contains supplementary material, which is available to authorized users.

IMPORTANCEPatients with residual depressive symptoms face a gap in care because few resources, to date, are available to manage the lingering effects of their illness.OBJECTIVE To evaluate the effectiveness for treating residual depressive symptoms with Mindful Mood Balance (MMB), a web-based application that delivers mindfulness-based cognitive therapy, plus usual depression care compared with usual depression care only. DESIGN, SETTING, AND PARTICIPANTSThis randomized clinical trial was conducted in primary care and behavioral health clinics at Kaiser Permanente Colorado, Denver. Adults identified with residual depressive symptoms were recruited between March 2, 2015, and November 30, 2018. Outcomes were assessed for a 15-month period, comprising a 3-month intervention interval and a 12-month follow-up period.INTERVENTIONS Patients were randomized to receive usual depression care (UDC; n = 230) or MMB plus UDC (n = 230), which included 8 sessions delivered online for a 3-month interval plus minimal phone or email coaching support.MAIN OUTCOMES AND MEASURES Primary outcomes were reduction in residual depressive symptom severity, assessed using the Patient Health Questionaire-9 (PHQ-9); rates of depressive relapse (PHQ-9 scores Ն15); and rates of remission (PHQ-9 scores <5). Secondary outcomes included depression-free days, anxiety symptoms (General Anxiety Disorder-7 Item Scale), and functional status (12-Item Short Form Survey). RESULTS Among 460 randomized participants (mean [SD] age, 48.30 [14.89] years; 346 women [75.6%]), data were analyzed for the intent-to-treat sample, which included 362 participants (78.7%) at 3 months and 330 (71.7%) at 15 months. Participants who received MMB plus UDC had significantly greater reductions in residual depressive symptoms than did those receiving UDC only (mean [SE] PHQ-9 score, 0.95 [0.39], P < .02). A significantly greater proportion of patients achieved remission in the MMB plus UDC group compared with the UDC only group (PHQ-9 score, <5: β [SE], 0.38 [0.14], P = .008), and rates of depressive relapse were significantly lower in the MMB plus UDC group compared with the UDC only group (hazard ratio, 0.61; 95% CI, 0.39-0.95; P < .03). Compared with the UDC only group, the MMB plus UDC group had decreased depression-free days (mean [SD], 281.14 [164.99] days vs 247.54 [158.32] days; difference, days; t = −2.33; P = .02), decreased anxiety (mean [SE] General Anxiety Disorder-7 Item Scale score, 1.21 [0.42], P = .004), and improved mental functioning (mean [SE] 12-Item Short Form Survey score, −5.10 [1.37], P < .001), but there was no statistically significant difference in physical functioning.CONCLUSIONS AND RELEVANCE Use of MMB plus UDC resulted in significant improvement in depression and functional outcomes compared with UDC only. The MMB web-based treatment may offer a scalable approach for the management of residual depressive symptoms.

BackgroundMaternal morbidity estimations are not based on well-documented methodologies and thus have limited validity for informing efforts to address the issue and improve maternal health. To fill this gap, maternal morbidity needs to be clearly defined, driving the development of tools and indicators to measure and monitor maternal health. This article describes the scoping exercise conducted by the World Health Organization’s Department of Reproductive of Health and Research (WHO/RHR), as an essential first step in this process.MethodsA literature review was conducted to identify the range of definitions and conditions included in various studies of maternal morbidity with a special focus on the similarities and discrepancies of the definitions used across the studies. Furthermore a questionnaire was developed which included sections on key areas identified during the review and was sent out electronically to 130 international experts in the field of maternal health.ResultsMaternal morbidities have been categorized in a variety of ways based on the causes, types of complications, and/or timeline. Issues regarding the time frame, severity, identification and classification and demographics were identified as key areas in the literature that require further investigation to achieve consensus on a maternal morbidity definition. Fifty-five (N = 55) individuals responded with completed questionnaires. Respondents’ views on the time frame for the postpartum period varied from 6 weeks to beyond one year postpartum, it was noted that time frame depended on the type of complication. The majority of respondents said maternal morbidity should comprise a continuum of severity, whereas the identification of the cases should use a mixed criteria employing multiple methods.ConclusionsSignificant discrepancy in literature and expert opinion exists concerning elements of a maternal morbidity definition. There is a clear need for a concrete definition that would allow for consistent measurement and monitoring of maternal morbidity across settings and time.

No abstract

Evaluating initiatives implemented across multiple settings can elucidate how various contextual factors may influence both implementation and outcomes. Understanding context is especially critical when the same program has varying levels of success across settings. We present a framework for evaluating contextual factors affecting an initiative at multiple phases of its life cycle, including design, implementation, scale-up, spread, and sustainability. After providing a brief overview of related frameworks from the fields of improvement science and implementation science and of the methods by which we drew from this literature to develop the current framework, we present how this framework was customized and applied to three national public health initiatives. We close with implications for how evaluators can apply the framework to facilitate a deeper understanding of a program's implementation and success, collaborate with project stakeholders, and facilitate sustainability, spread, and scale-up of public health initiatives.

No abstract

Cancer survivors reported significant unmet need for psychological intervention, preference for non-pharmacological forms of such support, and a gap between their preferred forms of support and what they currently receive.